Icon

AUBAGIO (nda202992)- (7MG,14MG)

TERIFLUNOMIDE SANOFI AVENTIS US
7MG,14MG
Yes No
2034-Aug-04 2017-Sep-12
None None
None No
AUBAGIO is a pyrimidine synthesis inhibitor indicated for the treatment of patients with relapsing forms of multiple sclerosis.
12 0 10
Total Other Developers 10
Drugs with Suitability No
7MG ** ** - - 7
14MG ** ** - 5 1
NDA Sales Available Total Generic Sales Available
Yes 4
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ******* ******* *************** ******* *********** *********** ********, ******* *******, *.*. *******, **** *****, ****** *****,, **********, ******* ******, ***** (***) ***
****** ******** ****** ******** *************** ******* *********** **** **. *, *****-*, ****** **** *** *********, ****, ****** ******* ******, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. ***/***-****** / **** **.***/****-*********** , *******-***** ******* , ****** -******, ******, *********, ******* ******, ***** (***) ***
****** ***** ***** ****** ******* *********** ****** ********, ******, **********, ********* *** ***, ***** (***) ***
****** ****** **** *** * ****** ****** ******* ******* *********** ****** **. ***, ******* *******, *********** ******,, **********, ********* ******, ***** (***) ***
****** ****** ****** ****** ****** ******* *********** ******* ******** ****, ***** **, **** **.*, ***** **, *********** - ****** **** ****, *********** ****, *********, ********* ******, ***** (***) ***
****** **** ****** ******* ***** (*****) ******* *********** **** *** *** ********** ******, *** ***, **********, *** ****, ***** (***) ***
****** ****** ****** ** ****** *************** ******* ******* *********** **** ** ** & **, ******* ******* ******** **** *******-***** *.*. **. **, ***.: ******, ***.: ******, *********, ** ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.